For a pdf copy of my complete CV, click here.
Faculty, Center for Bioethics, Harvard Medical School (2015- )
Research Fellow, Brigham and Women’s Hospital (2015- )
Visiting Researcher, Center for Philosophy and History of Science, Boston University (2015- )
Research Fellow, Biomedical Ethics Unit, McGill University (2012-2015)
Ph.D. Philosophy, University of Western Ontario (2012)
M.A. Philosophy, University of Western Ontario (2006)
B.A. (Honors) Philosophy, University of Illinois at Chicago (2004)
Canadian Institutes of Health Research, Project Grant (2017-2021)
Co-investigator, “Developing a Framework for the Ethical Design and Conduct of Pragmatic Trials”
Laura and John Arnold Foundation (2017-2020)
Principal Investigator, “Program on Regulation, Therapeutics, and Law (PORTAL) Biomarker Research Consortium”
Canadian Institutes of Health Research, Project Grant (2016-2020)
Co-investigator, “Ethics, Efficiency, and Patient Burden in Drug Development”
Hey SP (2017). Ethical Challenges in Biomarker-Driven Drug Development. Clinical Pharmacology & Therapeutics doi:10.1002/cpt.862.
Hey SP, Cohen IG, Adashi EY, Kesselheim AS (2017). Influence, Integrity, and the FDA: An Ethical Framework Science 357(6354):876-877.
Hey SP, Franklin JM, Avorn J, Kesselheim AS (2017). Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors Circulation: Cardiovascular Quality and Outcomes 10(6):e003121.
Hey SP (2017). Clinical trial participants should have a say in new drug pricing. STAT News, May 18.
Hey SP & Barsanti-Innes B (2017). Epistemology, Ethics, and Progress in Precision Medicine. Perspectives in Biology and Medicine 59(3):293-310.
Hey SP & Kesselheim AS (2017). Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations. Hastings Center Report 47(2):16-20.
Hey SP (2017). Priority, Prediction and the Ethical Research Enterprise. Journal of Medical Ethics doi:10.1136/medethics-2016-103999.
Barsanti-Innes B, Hey SP, & Kimmelman J (2017). The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing. The Oncologist 22(1):89-96.
Hey SP & Kesselheim AS (2016).The FDA, Juno Therapeutics, and the Ethical Imperative of Transparency. BMJ 354:i4435.
Hey SP & Kesselheim AS (2016). Countering Imprecision in Precision Medicine. Science 353(6298):448-449.
Kesselheim AS, Hey SP, Deak D, & Lo B (2016). Four Ways To Address The Ethical Tensions Around Expedited Approval Of New Prescription Drugs. Health Affairs Blog June 23.
Hey SP & Kimmelman J (2016). Do We Know Whether Researchers and Reviewers Are Estimating Risk and Benefit Accurately? Bioethics 30(8):609-617.
Hey SP & Weijer C (2016). What Questions Can A Placebo Answer? Monash Bioethics Review 34(1):23-36.
Kimmelman J & Hey SP (2016). Ensemble Space and the Ethics of Clinical Development. In Ethics and Governance in Biomedical Research, eds. D Strech & M Mertz, Springer International:137-151.
Hey SP (2016). Heuristics and Meta-heuristics in Scientific Judgement. The British Journal for the Philosophy of Science 67(2):471-495.
Hey SP & Kesselheim AS (2016). An Uninformative Truth: The Logic of Amarin’s Off-Label Promotion. PLoS Medicine 13(3):e1001978.
Carlisle B, Demko N, Freeman G, Hakala A, MacKinnon N, Ramsay T, Hey SP, London AJ, & Kimmelman J (2016). Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. Journal of the National Cancer Institute 108(1):djv292.
“Precision Medicine and Pragmatic Trials: Friends or Foes?” Annual Society for Clinical Trials Meeting, Liverpool, UK; May 2017.
“Ethical Considerations in Pragmatic Cluster Randomized Trials.” Research Ethics Consortium, Harvard Medical School; February 2017.
“The Hope and Hype of Precision Medicine.” Health Policy and Bioethics Consortium, Harvard Medical School; November 2016.
“Explanation in Biomedicine: Diagnosing the Problems, Prescribing a Solution.” Reductionism and Integration, Bioethics and Behavior: A Conference Celebrating the Career of Kenneth F. Schaffner, University of Pittsburgh; September 2016.
“Explanatory Agnosticism in Translational Medicine” with James Overton. Society for Philosophy of Science in Practice (SPSP) Conference. Glassboro, NJ; June 2016.
“The Imprecision of Precision Medicine.” Department of Population Health, New York University Medical Center; February 2016.